Evaluating the clinical endpoint of antibiotic prophylaxis for cirrhosis patients complicated with upper gastrointestinal bleeding: An updated systematic review and meta-analysis
https://doi.org/10.47895/amp.vi0.10174
- Author:
Putu Itta Sandi Lesmana Dewi
1
;
Kadek Mercu Narapati Pamungkas
1
;
Ni Luh Putu Yunia Dewi
1
;
Ni Nyoman Gita Kharisma Dewi
1
;
Dwijo Anargha Sindhughosa
1
,
2
;
I Ketut Mariadi
1
,
2
Author Information
1. Centre Research for Alimentary and Hepatobiliary System, Bali, Indonesia
2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine Udayana University - Prof. Dr. I.G.N.G. Ngoerah General Hospital, Bali, Indonesia
- Publication Type:Review
- Keywords:
variceal bleeding
- MeSH:
Antibiotic;
Anti-Bacterial Agents;
prophylaxis;
prevention & control;
Cirrhosis;
Fibrosis
- From:
Acta Medica Philippina
2024;58(Early Access 2024):1-10
- CountryPhilippines
- Language:English
-
Abstract:
Background and Objective:Antibiotic prophylaxis is used to prevent bacterial infections and rebleeding in cirrhosis patients with upper gastrointestinal bleeding (UGIB). However, the effects of various antibiotics on patients with UGIB are still being considered. This study aims to evaluate the effect of antibiotic prophylaxis on cirrhosis patients with UGIB.
Methods:The studies were searched through databases of PubMed, ScienceDirect, Wiley Online Library, and CENTRAL from 2013 to 2023. We used Revman 5.4 to perform a meta-analysis. I2 statistics measured the heterogeneity test. The odds ratio (OR) and 95% confidence interval (CI) were used to assess the effect of antibiotic prophylaxis.
Results:Twelve studies involving 14,825 cirrhosis patients were included in this study. Based on the meta-analysis, antibiotic prophylaxis significantly lowered the bacterial infection rate (OR: 0.29, 95%CI: 0.10 to 0.84, P = 0.02), and the incidence of serious adverse events (SAE) (OR: 0.50, 95%CI: 0.28 to 0.88, P = 0.02) in cirrhosis patients with UGIB.
Conclusions:Administration of antibiotics demonstrated a significant reduction in bacterial infection rates and SAEs. Broad-spectrum non-absorbable antibiotics can be used in cirrhosis patients with UGIB. The appropriate use of antibiotics is important to prevent resistance.
- Full text:202412010116180387010174-Article Text-178681-1-10-20240918.pdf
